China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its investigational therapy, NR-20201. This allogeneic adipose-derived mesenchymal stem cell therapy is in development for the treatment of acute ischemic stroke.
Preclinical study results have shown that the drug can synergistically interact with vascular endothelial cells through a cell homing mechanism, activating vascular regeneration and functional repair in damaged brain tissue. Currently, there is no similar product commercially available globally.- Flcube.com
